| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 1,936 | 66,769 | 1,579 | 463 |
| Research and development | 99,233 | 112,554 | 99,841 | 84,612 |
| General and administrative | 69,458 | 65,721 | 57,369 | 56,652 |
| Total operating expenses | 168,691 | 178,275 | 157,210 | 141,264 |
| Operating loss | -166,755 | -111,506 | -155,631 | -140,801 |
| Interest expense | 11,353 | 11,084 | - | 8,928 |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 14,969 | 13,181 | 14,078 | 13,370 |
| Interest and other expense, net | - | - | 8,868 | - |
| Interest and other income, net | 10,248 | 13,001 | 13,701 | 17,054 |
| Change in fair value of derivative liabilities | 700 | 3,000 | -400 | 700 |
| Change in fair value of liabilities related to rpi transactions | -2,800 | -14,600 | 3,900 | -15,200 |
| Debt conversion expense | 121,249 | - | - | - |
| Net loss | -306,178 | -134,370 | -161,376 | -160,545 |
| Unrealized gain (loss) on available-for-sale securities, net | 167 | -851 | -541 | 6,535 |
| Foreign currency translation adjustments | 25 | -852 | -312 | -126 |
| Comprehensive loss | -305,986 | -136,073 | -162,229 | -154,136 |
| Earnings per share, basic, total | -2.55 | -1.12 | -1.36 | -1.36 |
| Earnings per share, diluted, total | -2.55 | -1.12 | -1.36 | -1.36 |
| Weighted average number of shares outstanding, basic, total | 119,982 | 119,457 | 118,496 | 117,685 |
| Weighted average number of shares outstanding, diluted, total | 119,982 | 119,457 | 118,496 | 117,685 |
CYTOKINETICS INC (CYTK)
CYTOKINETICS INC (CYTK)